
InjectiveINJ
Live Injective price updates and the latest Injective news.
price
sponsored by
$8.74
$0
(0%)
24h low
$8.42
24h high
$8.84
The live Injective price today is $8.74 with a 24-hour trading volume of $72.54M. The table above accurately updates our INJ price in real time. The price of INJ is down -0.00% since last hour, up 0.54% since yesterday. The live market cap, measured by multiplying the number of coins by the current price is $874.00M. INJ has a circulating supply of 97.73M coins and a max supply of 100.00M INJ.
Injective Stats
What is the market cap of Injective?
The current market cap of Injective is $854.42M. A high market capitalization implies that the asset is highly valued by the market.
What is the current trading activity of Injective?
Currently, 8.30M of INJ were traded within 24 hours of time. In other words, $72.54M have changed hands within the past 24 hours through trading. That's a change of 0.54%.
What is the current price of Injective?
The price of 1 Injective currently costs $8.74.
How many Injective are there?
The current circulating supply of Injective is 97.73M. This is the total amount of INJ that is available.
What is the relative popularity of Injective?
Injective (INJ) currently ranks 93 among all known cryptocurrency assets. The popularity is based on relative market cap.
market data
$ 854.42M
0.54 %
#93
$ 72.54M
98,000,000
Get the daily newsletter that helps thousands of investors understand the markets.
recent research
Research
Telegram trading bots have found their primary niche in highly speculative token launches and retail-dominated memecoin markets, with many features specifically tailored to token sniping and copy-trading strategies.
by Danny K
/
Research
Bluefin possibly stands at an inflection point. The token is near an all-time low yet the protocol’s spot volume market share and derivatives exchange usage have been increasing month over month since its November launch. Given its current market position and the upcoming upgrades (for both Bluefin and SUI), there may be upside potential before the increased supply growth in December. However, strong opposition from existing competitors (like Cetus and Suilend), as well as new entrants (like Aftermath), pose key challenges to Bluefin’s medium-term success.